Literature DB >> 27804107

Improving Therapeutic Odyssey: Preemptive Pharmacogenomics Utility in Patient Care.

K N Lazaridis1.   

Abstract

Pharmacogenomics, studying genetic variation related to drug response, was established decades ago. Today, performing clinical pharmacogenomics testing has increased, creating great potential to improve patient care. Yet widespread implementation of pharmacogenomics in practice is currently limited, resulting in the "therapeutic odyssey" of patients. Preemptive clinical pharmacogenomics testing prior to the time of prescribing is now emerging as an option that could tailor the pharmacotherapy of patients by increasing drug effectiveness while reducing adverse drug reaction risk.
© 2016 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27804107     DOI: 10.1002/cpt.543

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

Review 1.  Progress, Challenges, and Prospects of Research on the Effect of Gene Polymorphisms on Adverse Reactions to Opioids.

Authors:  Jinsong Zhao; Shihong Cai; Long Zhang; Yuefeng Rao; Xianhui Kang; Zhiying Feng
Journal:  Pain Ther       Date:  2022-04-16

Review 2.  Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome.

Authors:  Dan M Roden; Sara L Van Driest; Jonathan D Mosley; Quinn S Wells; Jamie R Robinson; Joshua C Denny; Josh F Peterson
Journal:  Clin Pharmacol Ther       Date:  2018-03-13       Impact factor: 6.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.